摘要
目的探析密盖息联合仙灵骨葆胶囊治疗骨质疏松症的疗效。方法将2011年4月~2017年12月在我院接受治疗的311例骨质疏松症患者作为研究对象,采用随机分配的方法进行分组,两组患者均给予钙尔奇-D治疗,对照组(n=155)增加密盖息治疗,观察组(n=156)给予密盖息联合仙灵骨葆胶囊治疗,比较两组的治疗有效性和安全性。结果通过比较两组的治疗有效率,发现观察组的总有效率显著高于对照组,差异有统计学意义(P<0.05);通过对两组治疗前后骨密度的变化情况进行比较,发现治疗后两组患者的腰椎和股骨颈骨密度较治疗前均增加,且观察组明显优于对照组,差异有统计学意义(P<0.05);经比较两组治疗前后的骨代谢指标,发现治疗后两组的血清钙、血清磷、碱性磷酸酶较治疗前均增加,且观察组明显优于对照组,差异有统计学意义(P<0.05);经比较两组的用药安全性,观察组与对照组患者治疗期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论在骨质疏松症的临床治疗上,采用密盖息联合仙灵骨葆胶囊的方案进行治疗效果显著,可改善患者的骨密度和骨代谢,且安全性高,能够提升患者的生活质量,值得推广和应用。
Objective To explore and analyze the curative effect of miacalcic combined with xianling gubao capsules in the treatment of osteoporosis. Methods 311 patients with osteoporosis who were treated in our hospital from April 2011 to December 2017 were selected as main research objects.They were divided into two groups according to the random distribution method.Patients in two groups were all treated by caltrate-D.155 patents in the control group were treated by miacalcic on basis of caltrate-D while 156 patients in the observation group were treated by xianling gubao capsules on basis of caltrate-D.The efficacy and safety of the two groups were compared. Results By comparing the effective rates of treatment of the two groups,the total effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P < 0.05).By comparing the changes of bone mineral density before and after treatment,it was found that the bone mineral density of lumbar vertebrae and femur in both groups were increased after treatment,and those of the observation group were significantly better than those of the control group.The difference was statistically significant(P < 0.05).By comparing the bone metabolism indexes before and after treatment,it was found that serum calcium,serum phosphorus and alkaline phosphatase of two groups were increased after treatment,and those of the observation group were significantly better than those of the control group.The difference was statistically significant(P < 0.05).After comparing the medication safety of the two groups,there was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group during the treatment(P > 0.05). Conclusion In the clinical treatment of osteoporosis,the curative effect of miacalcic combined with xianling gubao capsules is significant. It can improve the bone mineral density and bone metabolism of patientsand it has high safety.It can improve the quality of life of patients,which is worth promoting and applying.
作者
郭险峰
GUO Xianfeng(The Seventh Hospital of Wuhan,Hubei,Wuhan 430071,China)
出处
《中国医药科学》
2019年第14期227-229,共3页
China Medicine And Pharmacy
